Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026
February 3, 2026
-
AlzeCure Pharma selected to present at the Bio-Neuroscience conference in Amsterdam
February 2, 2026
-
AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer’s disease
December 3, 2025